Objective: To investigate the value of red blood cell distribution width (RDW) and fibrinogen (Fib) level for the evaluation of therapeutic efficacy and prognosis in patients with diffuse large B-cell lymphoma (DLBCL).
Methods: The relationship between RDW/Fib at initial diagnosis and efficacy and the clinical outcome was retro-spectively analyzed based on the study of 105 patients with DLBCL. The patients were divided into two groups: low RDW group (≤15%) and high RDW group (>15%), low Fib group (Fib≤4 g/L) and high Fib group (Fib>4 g/L) according to the normal values of RDW and Fib. Therapeutic efficacy, overall survival (OS) time and progression free survival (PFS) time were compared between two groups. The correlation between each factors and efficacy, prognosis was analyzed by univariate and multivariate regression.
Results: The therapeutic efficacy (P<0.001), OS time(P=0.004), and PFS time(P=0.007) were poorer in the high RDW group as compared with the low RDW group. The efficacy (P=0.015) and PFS time(P=0.04) were poorer in the high Fib group as compared with the low Fib group. Multivariate analysis showed that high RDW was the independent risk factor for efficacy of DLBCL patients (OR=3.394, 95% CI 1.093-10.539, P=0.035).
Conclusion: High RDW and high Fib associate with poor efficacy in DLBCL patients.
题目: 红细胞分布宽度和纤维蛋白原水平对判断弥漫大B细胞淋巴瘤患者疗效及预后的价值.
目的: 探讨红细胞分布宽度（Red cell distribution width, RDW）和纤维蛋白原（Fibrinogen, Fib）在弥漫大B细胞淋巴瘤（DLBCL）患者疗效及预后中的价值.
方法: 回顾性分析105例DLBCL患者初诊时的RDW、Fib与临床特征及转归的关系，根据RDW、Fib正常值将患者分为低RDW组（≤15％）和高RDW组（＞15％）、低Fib组（Fib≤4 g/L）和高Fib组（Fib ＞4 g/L），比较2组患者疗效、总生存期（overall survival, OS）及疾病无进展生存期（progression free survival, PFS），单因素和多因素回归分析各指标与疗效及预后的关系.
结果: 高RDW与低RDW组相比，高RDW组疗效（P＜0.001）、OS（P=0.004）和PFS（P=0.007）均较差；高Fib组与低Fib组相比，高Fib组疗效（P=0.015）和PFS（P=0.04）较差；多因素分析显示，高RDW是影响DLBCL患者疗效的独立危险因素(OR=3394,95%CI 1.093-10.539,P=0.035).
结论: 高RDW、高Fib与DLBCL患者较差的疗效及不良预后相关.